252 related articles for article (PubMed ID: 31380271)
1. Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies.
Butters O; Young K; Cunningham D; Chau I; Starling N
Front Oncol; 2019; 9():618. PubMed ID: 31380271
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.
Young K; Chau I
Drugs; 2016 Jan; 76(1):13-26. PubMed ID: 26620367
[TBL] [Abstract][Full Text] [Related]
3. Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.
van der Woude SO; van Laarhoven HW
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27539134
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Smyth EC; Tarazona N; Chau I
Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
[TBL] [Abstract][Full Text] [Related]
6. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for oesophagogastric cancer.
Davidson M; Chau I
Expert Opin Biol Ther; 2016 Oct; 16(10):1197-207. PubMed ID: 27409159
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenesis in cancer therapeutics: the magic bullet.
Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
[TBL] [Abstract][Full Text] [Related]
9. VEGF inhibitors in cancer therapy.
Cardones AR; Banez LL
Curr Pharm Des; 2006; 12(3):387-94. PubMed ID: 16454752
[TBL] [Abstract][Full Text] [Related]
10. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with ramucirumab : outcomes in breast cancer.
O'Sullivan Coyne G; Burotto M
Expert Opin Biol Ther; 2014 Sep; 14(9):1351-60. PubMed ID: 25018016
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor a inhibition in gastric cancer.
Park DJ; Thomas NJ; Yoon C; Yoon SS
Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for anti-vascular endothelial growth factor drugs.
Kuriyama S; Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Miyasaka T; Yokoyama Y; Shinji S; Sonoda H; Ohta R; Yonaga K; Kanaka S; Yoshida H
Oncol Lett; 2022 Dec; 24(6):463. PubMed ID: 36406183
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
Lacal PM; Graziani G
Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
[TBL] [Abstract][Full Text] [Related]
15. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence.
De Luca E; Marino D; Di Maio M
Cancer Manag Res; 2020; 12():3721-3729. PubMed ID: 32547208
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of ramucirumab in advanced gastric cancer.
Chan MM; Sjoquist KM; Zalcberg JR
Biologics; 2015; 9():93-105. PubMed ID: 26451083
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall RD; Le TM; Haggstrom DE; Gentzler RD
Transl Lung Cancer Res; 2015 Oct; 4(5):515-23. PubMed ID: 26629420
[TBL] [Abstract][Full Text] [Related]
19. Update on clinical trials targeting vascular endothelial growth factor in cancer.
Bergsland EK
Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S12-20. PubMed ID: 15552622
[TBL] [Abstract][Full Text] [Related]
20. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
